[Ip-health] S.1810 proposal for National Academies study on delinkage

James Love james.love at keionline.org
Mon Jul 15 09:40:18 PDT 2019


Sorry about the title, it is S.1801, not 1810.

On Mon, Jul 15, 2019 at 12:37 PM James Love <james.love at keionline.org>
wrote:

> S. 1801: Affordable Medications Act
> Ms. Smith (for herself, Ms. Klobuchar, Mr. Blumenthal, Mr. Udall, Mr.
> Brown, Ms. Warren, Mr. Sanders, Ms. Hassan, Mr. Whitehouse, Mr. Merkley,
> Mr. Reed, Ms. Baldwin, Mr. Booker, Mr. Durbin, and Mrs. Gillibrand)
> introduced the following bill; which was read twice and referred to the
> Committee on Finance
>
> https://www.govtrack.us/congress/bills/116/s1801/text
>
> (j)Study
>
> (1)In general
>
> The Director of NIH shall seek to enter into an agreement with the
> National Academies of Sciences, Engineering, and Medicine to conduct a
> study to examine—
>
> (A)the use of innovation inducement reward funds and push financing
> mechanisms as ways to stimulate investments in biomedical research and
> development that de-links costs from product prices;
>
> (B)models of different possible means of de-linking research and
> development costs from drug prices, including the progressive replacement
> of the monopoly on new products with a combination of expanded research
> subsidies and new incentives from innovation inducement funds to stimulate
> the development of drugs, including drugs to treat bacterial infections,
> rare diseases, HIV/AIDS, and cancer;
>
> (C)the size of market entry rewards, open source dividends and other
> innovation inducement prizes that would be necessary to achieve innovation
> objectives and the relative cost effectiveness of incentives delinked from
> the prices of products and services in stimulating innovation, compared to
> time-limited monopolies; and
>
> (D)methods of progressively implementing policies that delink research and
> development funding from prices of products and services, including to the
> progressive reduction in the effective term of exclusive rights,
> accompanied by a progressive introduction and expansion of market entry
> rewards.
>
> (2)Authorization of appropriations
>
> For the purpose of carrying out this subsection, there are authorized to
> be appropriated, and there are appropriated, $3,000,000 for fiscal year
> 2020. Such funds shall remain available until expended.
>


-- 
James Love.  Knowledge Ecology International
U.S. Mobile +1.202.361.3040
U.S. office phone +1.202.332.2670
http://www.keionline.org <http://www.keionline.org/donate.html>
twitter.com/jamie_love


More information about the Ip-health mailing list